Board of Directors

• Stephen Bloch, M.D.- Chairman
• John M. Krayacich
• Nicole Vitulo
• Anand Mehra, M.D.

Steven Bloch, M.D.

Chairman

Stephen Bloch, MD joined Canaan Partners in June, 2002, initially as a Ewing Marion Kauffman Fellow. His investment targets include biopharmaceuticals (therapeutics and diagnostics), medical devices and healthcare infrastructure. Steve currently serves on the Board of Directors for Advanced Biohealing, Amicus Therapeutics, Marinus Pharmaceuticals, OmniSonics Medical Technologies and Viacor.

Prior to joining Canaan, Steve was a medical entrepreneur and practicing physician. He founded and was CEO of Radiology Management Sciences (RMS), a risk manager of diagnostic imaging services for health plans and provider networks. As medical director, he helped start Omnisonics Medical Technologies which is developing breakthrough products using acoustic energy for the treatment of vascular occlusive diseases. Additionally, he co-founded TeleRad, a teleradiology services company, and was an initial investor in OpenAir.com, an enterprise software company for professional services firms. Dr. Bloch started his business career as a strategic consultant with Arthur D. Little focused on pharmaceuticals and medical devices.

Dr. Bloch received his medical training as a radiologist at The Massachusetts General Hospital/Harvard Medical School and in internal medicine at The Lenox Hill Hospital/Cornell Medical School. He received his medical degree from the University of Rochester. He also received a MA in history of science and public policy from Harvard University and an AB degree in history from Dartmouth College.

Dr. Bloch became Chairman of the Marinus Pharmaceuticals Board in October 2007.

John M. Krayacich

President & Chief Executive Officer

John Krayacich joined Marinus Pharmaceuticals in 2008 as President, Chief Executive Officer and director after serving as the global head of neuroscience project management at Novartis Pharmaceuticals Corporation. As part of his role at Novartis, Mr. Krayacich acted as vice president and global program head of agomelatine, the first melatonergic antidepressant, and led the neuroscience drug development teams in the areas of major depressive disorder, general anxiety disorders, Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, spinal cord injury and bipolar disorder.

Prior to joining Novartis in 2003, Mr. Krayacich was Vice President of worldwide marketing (neurology) at Pfizer Pharmaceuticals, where he was responsible for a global marketing strategy and new product development.

Mr. Krayacich has more than 20 years of experience in the pharmaceutical industry with an emphasis on neurology product development and marketing. He started his career with Parke-Davis/Warner-Lambert Canada and advanced through a series of assignments in sales, North American and worldwide marketing, business development and global drug development. His work has included the development and commercialization of Lipitor®, Neurontin®, Lyrica®, Accupril®, Exelon® Patch, Focalin XR® and several neuroscience NCEs currently in development.

Nicole Vitulo

Ms. Vitullo joined Domain in 1999 and became a Partner in 2004. She has full management responsibility for Domain Public Equity Partners, L.P. and is also involved in distribution/liquidation strategies for the public companies in Domain Associate’s venture capital portfolios. Present board memberships include Celator Pharmaceuticals, Cerexa, and Ruxton Pharmaceuticals. Past Board memberships include Onyx Pharmaceuticals and Eunoe. From 1992-1999, Ms. Vitullo was Senior Vice President at Rothschild Asset Management, Inc. where she had responsibility for the U.S. public market investments of International Biotechnology Trust plc and Biotechnology Investments Limited. From 1991-1992, Ms. Vitullo served as the Director of Corporate Communications and Investor Relations at Cephalon, a publicly traded biotechnology company. Prior to Cephalon, Ms. Vitullo spent 12 years at Eastman Kodak, most recently in Corporate Development where she was involved in the development management of Kodak’s venture capital activities.

Ms. Vitulo has received BA and MBA degrees from the University of Rochester.

Anand Mehra, M.D.

Anand Mehra, M.D.is a Principal with Sofinnova Ventures focused on biopharmaceuticals. Prior to Sofinnova, Anand worked in JP Morgan’s private equity and venture capital group. At JP Morgan, he was heavily involved in their investments in Phenomix, Kemia, and CardioKinetix, management of their public portfolio, and the firm’s spinout from the bank. Before joining the venture community, Anand was a consultant in McKinsey & Co’s pharmaceutical practice advising pharma and biotech on key strategic issues, Anand is currently a director of Marinus Pharmaceuticals and Gentha Pharmaceuticals. Anand received his M.D. from Columbia Medical School and graduated Phi Beta Kappa from the University of Virginia.